interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Lamotrigine

Generic competition · all medicines · read 12 November 2026

Is there a generic of Lamotrigine, and who makes it?

Lamotrigine appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 21 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came between 3.6 and 11.7 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Lamotrigine5 dosage-form groups in the Orange Book
21generic makers listed
  1. Lamotrigine appears in 5 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 21 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came between 3.6 and 11.7 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Four or more generic makers listed

Brand listed as marketed: Lamictal. 12 generic makers with 50 generic products listed as marketed; the first generic approval is dated 30 August 2006.

199019952000200520102015202020252030012brand 1994Aurobindo Pharma Ltd, first approval 27 January 2009Dr Reddys Laboratories Ltd, first approval 27 January 2009Jubilant Cadista Pharmaceuticals Inc, first approval 27 January 2009Rubicon Research Ltd, first approval 27 January 2009Taro Pharmaceutical Industries Ltd, first approval 27 January 2009Torrent Pharmaceuticals Ltd, first approval 27 January 2009Zydus Pharmaceuticals Usa Inc, first approval 27 January 2009Alembic Pharmaceuticals Ltd, first approval 13 January 2011Unichem Laboratories Ltd, first approval 6 October 2011Glenmark Pharmaceuticals Ltd, first approval 4 May 2012Alkem Laboratories Ltd, first approval 14 June 2013Ipca Laboratories Ltd, first approval 26 September 2024data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Aurobindo Pharma Ltd27 January 20094
Dr Reddys Laboratories Ltd27 January 20094
Jubilant Cadista Pharmaceuticals Inc27 January 20094
Rubicon Research Ltd27 January 20094
Taro Pharmaceutical Industries Ltd27 January 20094
Torrent Pharmaceuticals Ltd27 January 20094
Zydus Pharmaceuticals Usa Inc27 January 20096
Alembic Pharmaceuticals Ltd13 January 20114
Unichem Laboratories Ltd6 October 20114
Glenmark Pharmaceuticals Ltd4 May 20124
Alkem Laboratories Ltd14 June 20134
Ipca Laboratories Ltd26 September 20244

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, Extended Release, Oral

Four or more generic makers listed

Brand listed as marketed: Lamictal Xr. 10 generic makers with 49 generic products listed as marketed; the first generic approval is dated 26 December 2012.

200520102015202020252030010brand 2009Ph Health Ltd, first approval 26 December 2012Sciegen Pharmaceuticals Inc, first approval 4 January 2013Rubicon Research Ltd, first approval 17 June 2013Dr Reddys Laboratories Ltd, first approval 19 June 2013Actavis Elizabeth Llc, first approval 17 October 2013Torrent Pharmaceuticals Ltd, first approval 23 December 2013Amneal Pharmaceuticals Of New York Llc, first approval 30 November 2018Zydus Pharmaceuticals Usa Inc, first approval 1 April 2020Pharmobedient Consulting Llc, first approval 8 December 2021Alembic Pharmaceuticals Ltd, first approval 1 October 2024data datePatent 8637512 listed to expire 7 January 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Ph Health Ltd26 December 20126
Sciegen Pharmaceuticals Inc4 January 20135
Rubicon Research Ltd17 June 20132
Dr Reddys Laboratories Ltd19 June 20136
Actavis Elizabeth Llc17 October 20136
Torrent Pharmaceuticals Ltd23 December 20133
Amneal Pharmaceuticals Of New York Llc30 November 20186
Zydus Pharmaceuticals Usa Inc1 April 20206
Pharmobedient Consulting Llc8 December 20216
Alembic Pharmaceuticals Ltd1 October 20243

Patents and exclusivities still listed

  • 7 January 2029Patent 8637512 drug product

Tablet, Orally Disintegrating, Oral

Four or more generic makers listed

Brand listed as marketed: Lamictal Odt. 8 generic makers with 32 generic products listed as marketed; the first generic approval is dated 15 July 2013.

20052010201520202025203008brand 2009Impax Laboratories Inc, first approval 15 July 2013Ph Health Ltd, first approval 27 October 2015Sciegen Pharmaceuticals Inc, first approval 17 June 2016Ajanta Pharma Ltd, first approval 19 January 2021J Molner Holdings Inc, first approval 3 February 2022Taro Pharmaceutical Industries Ltd, first approval 7 October 2025Torrent Pharmaceuticals Ltd, first approval 8 January 2026Alembic Pharmaceuticals Ltd, first approval 25 February 2026data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Impax Laboratories Inc15 July 20134
Ph Health Ltd27 October 20154
Sciegen Pharmaceuticals Inc17 June 20164
Ajanta Pharma Ltd19 January 20214
J Molner Holdings Inc3 February 20224
Taro Pharmaceutical Industries Ltd7 October 20254
Torrent Pharmaceuticals Ltd8 January 20264
Alembic Pharmaceuticals Ltd25 February 20264

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Tablet, For Suspension, Oral

Four or more generic makers listed

Brand listed as marketed: Lamictal Cd. 6 generic makers with 13 generic products listed as marketed; the first generic approval is dated 21 June 2006.

1995200020052010201520202025203006brand 1998Dr Reddys Laboratories Ltd, first approval 22 January 2009Watson Laboratories Inc, first approval 22 January 2009Zydus Pharmaceuticals Usa Inc, first approval 22 January 2009Glenmark Pharmaceuticals Ltd, first approval 19 February 2009Aurobindo Pharma Ltd, first approval 4 November 2009Alembic Pharmaceuticals Ltd, first approval 12 June 2014data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Dr Reddys Laboratories Ltd22 January 20092
Watson Laboratories Inc22 January 20093
Zydus Pharmaceuticals Usa Inc22 January 20092
Glenmark Pharmaceuticals Ltd19 February 20092
Aurobindo Pharma Ltd4 November 20092
Alembic Pharmaceuticals Ltd12 June 20142

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Suspension, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Subvenite. No generic is listed as marketed.

2020202520302035204001brand 2025data datePatent 11596634 listed to expire 29 May 2040Patent 11612566 listed to expire 29 May 2040Patent 12629377 listed to expire 29 May 2040Patent 12636289 listed to expire 29 May 2040
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 29 May 2040Patent 11596634
  • 29 May 2040Patent 11612566
  • 29 May 2040Patent 12629377 drug product
  • 29 May 2040Patent 12636289 drug product

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.